Founded in 1993, SV Health Investors is a leading transatlantic VC firm with a long history of investing in innovative life sciences companies developing much needed therapeutics for patients to deliver positive financial returns to investors.
The firm manages ~$1.3bn in assets across its therapeutics funds which invest across the full spectrum of biotech companies - from later-stage growth opportunities to early-stage venture - harnessing innovative technology to improve drug development outcomes.
SV Health Investors maintains a significant presence in the UK life sciences ecosystem with an office in London, where Managing Partner Kate Bingham is based. SV Health Investors also has an office in Boston meaning SV Health Investors is deeply embedded in two of the key biotech hubs.
Recent exits include: EyeBio, sold to Merck & Co for up to $3bn including $1.5bn in upfront and near-term milestone payments and Nimbus, sold to Takeda for up to $6bn including $4bn upfront. EyeBio is a UK-based company SV created with third-time entrepreneur and SV Venture Partner to address common causes of blindness and Nimbus is developing best-in-class therapeutics to address immune-mediated diseases.
Reason for commitment from British Business Bank
The Bank first invested in an SV Health Investors fund in 2018 and has since made commitments to a total of five funds – three biotech and two dementia-focused.
Aligns with the Bank’s strategy to support the UK’s most promising companies in the life sciences sector.
Example previous investments by the manager
EyeBio (bought by Merck & Co for up to $3bn), Artios, Draig Therapeutics, Alchemab and Sitryx.
In December 2025, the Bank made its then largest ever commitment to SV8 Biotech Fund LP, $100m of the $500m target total fund size. The decision to do so followed the Bank’s robust due diligence process and Investment Committee approval.
-
Fund Manager
SV Health Investors
-
Based in
Transatlantic firm with well-established offices in both London & Boston
-
Stage
Multistage strategy with emphasis on de-risked later stage assets
-
Industrial Strategy Sectors
Life Sciences
-
Structure
GP/LP
-
Fundraising target
$500 million
-
British Business Bank Commitment
$100 million - November 2025
Disclaimer
This website includes information about UK investment funds in which one or more entities within the British Business Bank group (“BBB Group”) may be investors. This information is provided for information purposes only – it has no regard to the specific investment objectives or particular needs of any person and does not constitute an offer, recommendation, or financial promotion under applicable legislation. The BBB Group does not market or make investment opportunities available to the public. Fund details are provided by external sources and the BBB Group does not verify their accuracy. Fund investments involve significant risk, including the risk of losing capital.
Access to this website is intended for authorised persons only. Users are responsible for complying with local laws and regulations regarding access. Any investment enquiries must be directed to the relevant fund manager and any investment decisions must be based solely on information provided by the relevant fund or fund manager.
